Is T790M mutation the key in development of esistance to epidermal growth factor receptor tyrosine kinase nhibitors (EGFR-TKIs)?

Over the last 2 decades, a number of new approaches were proposed in diagnosis and treatment of non-small cell lung cancer (NSCLC), which comprises about 80 to 85% of all lung cancers. For its diagnosis, gene expression profiling has recently been suggested as a predictive and prognostic biomarker in early-stage NSCLC (1). For its treatment, multiple modalities have been developed and introduced into clinical practice.